Members of the group are: M. Bjørneboe, P. Christoffersen, O. Dietrichson, V. Faber, G. Høybye, F. Hardt, M. Hilden, K. Iversen, O. Jessen, E. Juhl, J. Lindskov, S. Munksgaard, J. O. Nielsen, S. Nørregaard, H. Poulsen, H. Prytz, K. Ramsøe, L. Ranek, V. Reinicke, P. Schlichting, T. I. A. Sørensen, U. Tage-Jensen, Aa. C. Thomsen, N. Tygstrup and K. Winkler.
Malignancies following long-term azathioprine treatment in chronic liver disease
A report from the Copenhagen Study Group for Liver Diseases*
Article first published online: 10 DEC 2008
© 1987 Blackwell Munksgaard
Volume 7, Issue 2, pages 81–83, April 1987
How to Cite
Tage-Jensen, U., Schlichting, P., Thomsen, H. F., Høybye, G., Thomsen, Aa. C. and The Copenhagen Study Group for Liver Diseases (1987), Malignancies following long-term azathioprine treatment in chronic liver disease. Liver, 7: 81–83. doi: 10.1111/j.1600-0676.1987.tb00321.x
- Issue published online: 10 DEC 2008
- Article first published online: 10 DEC 2008
- Accepted for publication 23 October 1986
- chronic liver disease;
- malignant neoplasia
ABSTRACT— One hundred and fifty-four patients with histologically verified nonalcoholic chronic liver disease were randomized to azathioprine or prednisone treatment. After a median of 91 months observation time, the cause of death was assessed retrospectively. Autopsy was performed in 82% of 71 deaths. In the azathioprine group 33% (13/39) died from malignant neoplasia, and in the prednisone group (13%) (4/32) (p = 0.08). Considering a possible fatal outcome as a consequence of treatment, this finding urges caution in the long-term application of azathioprine at the usual dose level.